Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | HPGD | P15428 | 3/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.64 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9228116 | 0.82 | ALDH1A1 (0.70) | ALDH1A1HPGDGAAHSD17B10SIRT2 | |
| SCHEMBL5269737 | 0.82 | ALDH1A1 (0.79) | ALDH1A1HPGDGAAHSD17B10SIRT2 | |
| SCHEMBL820663 | 0.82 | ALDH1A1 (0.79) | ALDH1A1HPGDGAAHSD17B10SIRT2 | |
| SCHEMBL12856664 | 0.82 | ALDH1A1 (0.70) | ALDH1A1HPGDGAAHSD17B10SIRT2 | |
| SCHEMBL5269218 | 0.82 | ALDH1A1 (0.79) | ALDH1A1HPGDGAAHSD17B10SIRT2 | |
| SCHEMBL14852665 | 0.81 | ALDH1A1 (0.68) | ALDH1A1HPGDGAAHSD17B10SIRT2 | |
| SCHEMBL12200287 | 0.81 | ALDH1A1 (0.68) | ALDH1A1HPGDGAAHSD17B10SIRT2 | |
| SCHEMBL12200316 | 0.81 | ALDH1A1 (0.68) | ALDH1A1HPGDGAAHSD17B10SIRT2 | |
| SCHEMBL9223130 | 0.81 | ALDH1A1 (0.68) | ALDH1A1HPGDGAAHSD17B10SIRT2 | |
| SCHEMBL14430966 | 0.80 | ALDH1A1 (0.71) | ALDH1A1HPGDGAAHSD17B10SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012678-B2 | Processes for the preparation of fesoterodine | CADILA HEALTHCARE LIMITED (IN) | 2015-04-21 | — | — | US | claimed |
| US-20130197260-A1 | PROCESSES FOR THE PREPARATION OF FESOTERODINE | CADILA HEALTHCARE LIMITED (IN) | 2013-08-01 | — | — | US | claimed |
| WO-2012098560-A2 | PROCESS FOR THE PREPARATION OF MUSCARINIC RECEPTOR ANTAGONIST | MSN LABORATORIES LIMITED (IN) | 2012-07-26 | — | — | WO | claimed |
| WO-2012025941-A2 | PROCESSES FOR THE PREPARATION OF FESOTERODINE | CADILA HEALTHCARE LIMITED (IN) | 2012-03-01 | — | — | WO | claimed |
| EP-2545024-B1 | PROCESS FOR PREPARATION OF 3-(2-HYDROXY-5-SUBSTITUTED PHENYL)-3-PHENYLPROPYLAMINES, INTERMEDIATES FOR MAKING HYDROXYTOLTERODINE AND FESOTERODINE | LEK PHARMACEUTICALS (SI) | 2016-08-03 | — | — | EP | disclosed |
| US-9085509-B2 | Process for preparing fesoterodine | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2015-07-21 | — | — | US | disclosed |
| US-9085509-B2 | Process for preparing fesoterodine | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2015-07-21 | — | — | US | disclosed |
| US-9012678-B2 | Processes for the preparation of fesoterodine | CADILA HEALTHCARE LIMITED (IN) | 2015-04-21 | — | — | US | disclosed |
| US-9012678-B2 | Processes for the preparation of fesoterodine | CADILA HEALTHCARE LIMITED (IN) | 2015-04-21 | — | — | US | disclosed |
| US-9012678-B2 | Processes for the preparation of fesoterodine | CADILA HEALTHCARE LIMITED (IN) | 2015-04-21 | — | — | US | disclosed |
| US-8728705-B2 | Negative photosensitive material, photosensitive board employing the negative photosensitive material, and negative pattern forming method | NITTO DENKO CORPORATION (JP) | 2014-05-20 | — | — | US | disclosed |
| US-8722920-B2 | Process for obtaining 3, 3-diphenylpropylamines | CRYSTAL PHARMA S.A.U. (ES) | 2014-05-13 | — | — | US | disclosed |
| WO-1999058478-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SCHWARZ PHARMA AG (DE) | 1999-11-18 | — | — | WO | disclosed |
| EP-0957073-A1 | Novel derivatives of 3,3-diphenylpropylamines | SCHWARZ PHARMA AG (DE) | 1999-11-17 | — | — | EP | disclosed |
| EP-0667852-B1 | NOVEL 3,3-DIPHENYLPROPYLAMINES, THEIR USE AND PREPARATION | PHARMACIA & UPJOHN AB (SE) | 1998-04-08 | — | — | EP | disclosed |
| US-5686464-A | ANTICHOLINERGIC AGENTS; URINARY INCONTINENCE TREATMENT | PHARMACIA AB (SE) | 1997-11-11 | — | — | US | disclosed |
| US-5559269-A | ANTICHOLINERGIC AGENTS | PHARMACIA AB (SE) | 1996-09-24 | — | — | US | disclosed |
| EP-0667852-A1 | NOVEL 3,3-DIPHENYLPROPYLAMINES, THEIR USE AND PREPARATION | Pharmacia & Upjohn Aktiebolag (SE) | 1995-08-23 | — | — | EP | disclosed |
| WO-1994011337-A9 | NOVEL 3,3-DIPHENYLPROPYLAMINES, THEIR USE AND PREPARATION | — | 1995-07-06 | — | — | WO | disclosed |
| WO-1994011337-A1 | NOVEL 3,3-DIPHENYLPROPYLAMINES, THEIR USE AND PREPARATION | PHARMACIA AB (SE) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197260-A1 | PROCESSES FOR THE PREPARATION OF FESOTERODINE | QDPR, FES, SULT1A1 | ALDH1A1 849/4885HPGD 1750/4885GAA 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.